- Issuer ticker
-
PROCF
- Reported as of
-
18 Mar 2026
- Net transaction value
-
$0
Source evidence
Original filing metadata and source links for verification.
3 source fields
- SEC form
-
3
- Accepted by SEC
-
30 Mar 2026, 08:09:19 UTC
Reporting owner
1 detail
- Reporting owner signature
-
/s/ Freddy Andres Lozano Reyes, attorney-in-fact.
Key filing fact
Muniz Fernando Sebastian Moreira filed Form 3 for Sofgen Pharma S.A. (PROCF) on 30 Mar 2026.
Key facts
- This page summarizes Muniz Fernando Sebastian Moreira's Form 3 filing for Sofgen Pharma S.A. (PROCF).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 30 Mar 2026, 08:09.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
Ownership activity is grounded in SEC Form 3 disclosures.
View source filing
Reporting Owners (1)
CIK 0002124183
Primary reporting owner
Moreira Muniz Fernando Sebastian
- Relationship
-
Director, 10%+ Owner
- Address
- 11600 MIRAMAR PARKWAY, SUITE 300, MIRAMAR
- Signature
- /s/ Freddy Andres Lozano Reyes, attorney-in-fact.
- Signature date
- 30 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PROCF
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
-
- Shares after
- 305,309,149
- Date
- 18 Mar 2026
- Ownership
- By Becaril S.A.
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PROCF
holding
Derivative
Warrant to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
-
- Shares after
- Date
- 18 Mar 2026
- Ownership
- By Becaril S.A.
- Underlying class
- Ordinary Shares
- Underlying amount
- 19,800,411
- Exercise price
- $0.0631
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Explanation of responses
2 footnotes
SEC remarks
See Exhibit 24 - Power of Attorney.